Abstract | OBJECTIVE: DESIGN: RESULTS: In total, 81 patients were included in this analysis. Pregabalin 150-600 mg/day was associated with clinically meaningful and sustained pain reduction during each treatment cycle. During pregabalin " drug holidays," pain quickly returned to baseline levels; it was reduced again when pregabalin was reinstated. CONCLUSIONS: These results suggest that pregabalin may be beneficial in patients with neuropathic pain who have had an unsatisfactory response to treatment with other medications.
|
Authors | Brett R Stacey, Robert H Dworkin, Kevin Murphy, Uma Sharma, Birol Emir, Teresa Griesing |
Journal | Pain medicine (Malden, Mass.)
(Pain Med)
Vol. 9
Issue 8
Pg. 1202-8
(Nov 2008)
ISSN: 1526-4637 [Electronic] England |
PMID | 18346060
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics
- Placebos
- Pregabalin
- gamma-Aminobutyric Acid
|
Topics |
- Analgesics
(therapeutic use)
- Diabetic Neuropathies
(complications)
- Double-Blind Method
- Humans
- Neuralgia
(drug therapy, etiology)
- Neuralgia, Postherpetic
(complications)
- Pain Measurement
- Pain, Intractable
(drug therapy, etiology)
- Placebos
- Pregabalin
- Randomized Controlled Trials as Topic
- Surveys and Questionnaires
- Treatment Outcome
- gamma-Aminobutyric Acid
(analogs & derivatives, therapeutic use)
|